FDA confirms PRGN-2012 Phase 1/2 study as pivotal for accelerated approval; cash runway into 2025

PRECIGEN, INC.

FDA confirmed ongoing Phase 1/2 single-arm study of PRGN-2012 for RRP as pivotal for accelerated approval; no placebo trial needed.
Retired all outstanding convertible notes in Q2; cash, equivalents, and investments totaled $95.6M as of June 30, 2023.
Q2 2023 loss from continuing operations was $20.3M ($0.08/share), improved from $26.1M loss in Q2 2022.
SG&A expenses decreased 27% Q2 vs prior year; revenue fell 39% due to reduced services at Exemplar.
Projected cash runway into 2025; Phase 2 enrollment complete, data collection by Q2 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECIGEN, INC. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 9, 2023, reporting its financial results for the quarter ended June 30, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

PRECIGEN, INC. filing history →

Source: SEC EDGAR

accession 0000950103-23-011755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.